Compile Data Set for Download or QSAR
maximum 50k data
Found 2795 of ic50 for UniProtKB: P07949
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296817(US10112942, Example 552 | US10137124, Example 552 ...)
Affinity DataIC50:  1nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296817(US10112942, Example 552 | US10137124, Example 552 ...)
Affinity DataIC50:  1nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305704(2-chloro-N-((3S,4S)-1-(5- (3-cyano-6- ethoxypyrazo...)
Affinity DataIC50:  2nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296818(US10112942, Example 553 | US10137124, Example 553 ...)
Affinity DataIC50:  2nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296818(US10112942, Example 553 | US10137124, Example 553 ...)
Affinity DataIC50:  2nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284360(4-(6-(4-(5-cyclopropyl- 1H-pyrazole-3- carbonyl)pi...)
Affinity DataIC50:  2.5nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284117(US10023570, Example 127 | US10174027, Example 127)
Affinity DataIC50:  2.70nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284119(N-benzyl-4-(5-(3-cyano-6- (1-methyl-1H-pyrazol-4- ...)
Affinity DataIC50:  2.90nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296816(US10112942, Example 551 | US10137124, Example 551 ...)
Affinity DataIC50:  3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305765(2-chloro-N-(1-(5-(3- cyano-6- hydroxypyrazolo [1,5...)
Affinity DataIC50:  3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305759(3-chloro-N-(1-(5-(3- cyano-6- ethoxypyrazolo[1,5- ...)
Affinity DataIC50:  3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305757(3-chloro-N-(1-(5-(3- cyano-6- ethoxypyrazolo[1,5- ...)
Affinity DataIC50:  3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305705(2-chloro-N-((3S,4S)-1-(5- (3-cyano-6- ethoxypyrazo...)
Affinity DataIC50:  3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296816(US10112942, Example 551 | US10137124, Example 551 ...)
Affinity DataIC50:  3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM283931(US10023570, Example 4 | US10174027, Example 4)
Affinity DataIC50:  3.10nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284552(US10023570, Example 567 | US10174027, Example 567)
Affinity DataIC50:  3.10nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284088(4-(5-(3-cyano-6-(1-methyl-1H- pyrazol-4-yl)pyrazol...)
Affinity DataIC50:  3.60nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM283981((S)-4-(6-(4-(3- hydroxy-3- phenylpropanoyl)piperaz...)
Affinity DataIC50:  3.60nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305672(US10144734, Example 690 | US10172845, Example 690 ...)
Affinity DataIC50:  3.70nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305468(US10144734, Example 485 | US10172845, Example 485 ...)
Affinity DataIC50:  3.70nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284013(US10023570, Example 23 | US10174027, Example 23)
Affinity DataIC50:  3.80nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284350(4-(6-(4-(2-(5- fluoropyridin-2- yl)acetyl)piperazi...)
Affinity DataIC50:  3.90nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM283980((R)-4-(6-(4-(3- hydroxy-3- phenylpropanoyl)piperaz...)
Affinity DataIC50:  3.90nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284355(4-(6-(4-(2-(4- cyanophenyl)acetyl)pipera zin-1-yl)...)
Affinity DataIC50:  4nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296809(US10112942, Example 544 | US10137124, Example 544 ...)
Affinity DataIC50:  4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305752(US10144734, Example 770 | US10172845, Example 770 ...)
Affinity DataIC50:  4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305724(4-(6-(4-(3-fluorobenzyl)- 4-hydroxypiperidin-1- yl...)
Affinity DataIC50:  4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305707(N-((3S,4S)-1-(5-(3-cyano- 6-ethoxypyrazolo[1,5- a]...)
Affinity DataIC50:  4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296821(US10112942, Example 556 | US10137124, Example 556 ...)
Affinity DataIC50:  4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296809(US10112942, Example 544 | US10137124, Example 544 ...)
Affinity DataIC50:  4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296821(US10112942, Example 556 | US10137124, Example 556 ...)
Affinity DataIC50:  4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284226(1-(5-(3-cyano-6-(1- methyl-1H-pyrazol-4- yl)pyrazo...)
Affinity DataIC50:  4nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284174(US10023570, Example 184 | US10174028, Example 184)
Affinity DataIC50:  4nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284705(US10023570, Example 740 | US10174027, Example 740)
Affinity DataIC50:  4nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284041(4-(6-(4-(2,6- difluorobenzoyl)piperazin- 1-yl)pyri...)
Affinity DataIC50:  4.10nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305355(US10144734, Example 371 | US10172845, Example 371 ...)
Affinity DataIC50:  4.20nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284555(US10023570, Example 570 | US10174027, Example 570)
Affinity DataIC50:  4.20nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284123(4-(5-(3-cyano-6-(1-methyl- 1H-pyrazol-4- yl)pyrazo...)
Affinity DataIC50:  4.30nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284472(US10023570, Example 482 | US10174027, Example 482)
Affinity DataIC50:  4.40nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM305346(US10144734, Example 362 | US10172845, Example 362 ...)
Affinity DataIC50:  4.40nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284043(US10023570, Example 53 | US10174027, Example 53)
Affinity DataIC50:  4.40nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM283987((R)-6-(1-methyl-1H- pyrazol-4-yl)-4-(6-(4- (2- phe...)
Affinity DataIC50:  4.40nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284059(4-(6-(4-benzoylpiperazin-1- yl)pyridin-3-yl)-6-(1-...)
Affinity DataIC50:  4.40nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284068(6-(1-methyl-1H-pyrazol-4- yl)-4-(6-(4-(2- phenylac...)
Affinity DataIC50:  4.40nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284548(US10023570, Example 563 | US10174027, Example 563)
Affinity DataIC50:  4.40nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284476(US10023570, Example 489 | US10174027, Example 489)
Affinity DataIC50:  4.5nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284464(US10023570, Example 474 | US10174027, Example 474)
Affinity DataIC50:  4.5nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284232(US10023570, Example 242 | US10174027, Example 242)
Affinity DataIC50:  4.5nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM284129(US10023570, Example 139 | US10174027, Example 139)
Affinity DataIC50:  4.5nMpH: 7.4Assay Description:Compounds of General Formula I were screened for their ability to inhibit wild type and V804M mutant RET kinase using CisBio's HTRF® KinEASE -TK ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Eli Lilly

US Patent
LigandPNGBDBM296696(US10112942, Example 431 | US10137124, Example 431 ...)
Affinity DataIC50:  4.5nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 2795 total ) | Next | Last >>
Jump to: